What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
Frank Ruschitzka mainly investigates Internal medicine, Cardiology, Heart failure, Endocrinology and Intensive care medicine.
His Internal medicine study frequently links to other fields, such as Placebo.
Cardiology is closely attributed to Observational study in his research.
His Heart failure study combines topics from a wide range of disciplines, such as Blood pressure and Myocardial infarction, Cardiogenic shock.
In general Endocrinology study, his work on Vasodilation, Oxidative stress, Mineralocorticoid receptor and Spironolactone often relates to the realm of Dark chocolate, thereby connecting several areas of interest.
Frank Ruschitzka has included themes like Volume overload, Pharmacotherapy and MEDLINE in his Intensive care medicine study.
His most cited work include:
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. (9345 citations)
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (6276 citations)
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (3899 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cardiology, Heart failure, Ejection fraction and Endocrinology.
He integrates many fields in his works, including Internal medicine and In patient.
His Cardiology research includes themes of Clinical endpoint and Randomized controlled trial.
Frank Ruschitzka interconnects Hazard ratio, QRS complex, Clinical trial and Intensive care medicine in the investigation of issues within Heart failure.
His Endocrinology study frequently draws parallels with other fields, such as Bradykinin.
His Heart transplantation research also covers Transplantation and Surgery studies.
He most often published in these fields:
- Internal medicine (65.77%)
- Cardiology (43.78%)
- Heart failure (38.17%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (65.77%)
- Cardiology (43.78%)
- Heart failure (38.17%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Cardiology, Heart failure, Ejection fraction and Atrial fibrillation.
Frank Ruschitzka integrates Internal medicine and In patient in his research.
While the research belongs to areas of Cardiology, he spends his time largely on the problem of MEDLINE, intersecting his research to questions surrounding Takotsubo syndrome.
His Heart failure research integrates issues from Diabetes mellitus, Position paper and Intensive care medicine.
His Intensive care medicine research includes elements of Pharmacotherapy and Disease management.
His Atrial fibrillation study frequently draws connections to other fields, such as Cardiomyopathy.
Between 2018 and 2021, his most popular works were:
- Endothelial cell infection and endotheliitis in COVID-19. (2154 citations)
- RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. (604 citations)
- How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (221 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Disease
His scientific interests lie mostly in Internal medicine, Heart failure, Cardiology, Ejection fraction and Intensive care medicine.
By researching both Internal medicine and In patient, Frank Ruschitzka produces research that crosses academic boundaries.
His research in Heart failure intersects with topics in Diabetes mellitus, Renin–angiotensin system, Position paper and Myocarditis.
His biological study spans a wide range of topics, including Type 2 diabetes and Type 2 Diabetes Mellitus.
His studies deal with areas such as Canagliflozin, Anemia, Placebo, Dapagliflozin and Empagliflozin as well as Ejection fraction.
His research integrates issues of Presentation, Pulmonary congestion, Hypertension diagnosis and Lung ultrasound in his study of Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
